Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
dsf0qbxBnGQgnXC5
